{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T23:23:31Z","timestamp":1791501811191,"version":"4.3.4"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T00:00:00Z","timestamp":1725235200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>IL-12 signalling was proposed in the immunopathogenesis of primary Sj\u00f6gren\u2019s disease. The efficacy of therapies targeting this pathway is currently unclear. Herein, we investigated the associations between circulating proteins involved in the IL-12 and IL-23 signalling pathways on primary Sj\u00f6gren\u2019s disease using Mendelian randomization.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We selected single nucleotide polymorphisms from protein quantitative trait loci of IL12A, IL12B, IL12R\u03b21, IL12R\u03b22 and IL23R to examine the association between alterations in their levels and risk of primary Sj\u00f6gren\u2019s disease. Genetic association data for proteins were taken from studies ranging from 3301 to 54\u2009306 in sample size, and from 3232 cases of primary Sj\u00f6gren\u2019s disease and 17\u2009481 controls. The Wald ratio or inverse variance weighted methods estimated causal effects. We applied colocalization and pleiotropy-robust methods as sensitivity analyses for confounding.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>There was a negative association between genetically predicted IL-12p40 (encoded by IL12B) and primary Sj\u00f6gren\u2019s disease. In the two independent exposure datasets odds ratio (OR), 0.79 (95% CI 0.68\u20130.93; P-value\u2009=\u20090.004) and OR 0.86 (95% CI 0.78\u20130.95; P-value\u2009=\u20090.003) per S.D. decrease in genetically predicted IL-12p40. Neither IL-12R\u03b22 nor IL-23R met the threshold P-value after Mendelian randomization analyses (P-value &amp;lt; 0.01) for colocalization assessment. No variants for the IL12A gene met prerequisite thresholds for weak instrument bias.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>This study provides genetic evidence that IL-12p40 has a causal role in primary Sj\u00f6gren\u2019s disease pathogenesis. Our data suggest that decreasing levels of IL-12p40 may be deleterious. We would not suggest selecting this drug target as a therapeutic option.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keae475","type":"journal-article","created":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T19:00:59Z","timestamp":1725303659000},"page":"2295-2299","source":"Crossref","is-referenced-by-count":2,"title":["Association between interleukin-12 p40 subunit and risk of primary Sj\u00f6gren\u2019s disease: a Mendelian randomization study"],"prefix":"10.1093","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0077-6074","authenticated-orcid":false,"given":"Benjamin P","family":"Zuckerman","sequence":"first","affiliation":[{"name":"Centre for Rheumatic Diseases, King\u2019s College London , London,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zijing","family":"Yang","sequence":"additional","affiliation":[{"name":"Centre for Rheumatic Diseases, King\u2019s College London , London,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alasdair","family":"Warwick","sequence":"additional","affiliation":[{"name":"Institute of Cardiovascular Science, University College London , London,","place":["UK"]},{"name":"NIHR Biomedical Research Centre, Moorfields Eye Hospital NHS Foundation Trust , London,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Wincup","sequence":"additional","affiliation":[{"name":"Centre for Rheumatic Diseases, King\u2019s College London , London,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8171-7772","authenticated-orcid":false,"given":"Mark D","family":"Russell","sequence":"additional","affiliation":[{"name":"Centre for Rheumatic Diseases, King\u2019s College London , London,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1230-2781","authenticated-orcid":false,"given":"James B","family":"Galloway","sequence":"additional","affiliation":[{"name":"Centre for Rheumatic Diseases, King\u2019s College London , London,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3558-7353","authenticated-orcid":false,"given":"Sizheng Steven","family":"Zhao","sequence":"additional","affiliation":[{"name":"Faculty of Biological Medicine and Health, Centre for Musculoskeletal Research, School of Biological Sciences, The University of Manchester , Manchester,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,9,2]]},"reference":[{"key":"2025040212140435000_keae475-B1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/annrheumdis-2019-216114","article-title":"EULAR recommendations for the management of Sj\u00f6gren\u2019s syndrome with topical and systemic therapies","volume":"79","author":"Ramos-Casals","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2025040212140435000_keae475-B2","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.1093\/rheumatology\/kex375","article-title":"The British Society for Rheumatology guideline for the management of adults with primary Sj\u00f6gren\u2019s syndrome","volume":"56","author":"Price","year":"2017","journal-title":"Rheumatology"},{"key":"2025040212140435000_keae475-B3","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1038\/s41584-023-00932-6","article-title":"Genetics and epigenetics of primary Sj\u00f6gren syndrome: implications for future therapies","volume":"19","author":"Thorlacius","year":"2023","journal-title":"Nat Rev Rheumatol"},{"key":"2025040212140435000_keae475-B4","doi-asserted-by":"crossref","first-page":"e1008489","DOI":"10.1371\/journal.pgen.1008489","article-title":"Are drug targets with genetic support twice as likely to be approved? Revised estimates of the impact of genetic support for drug mechanisms on the probability of drug approval","volume":"15","author":"King","year":"2019","journal-title":"PLoS Genet"},{"key":"2025040212140435000_keae475-B5","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/s41588-020-0682-6","article-title":"Phenome-wide Mendelian randomization mapping the influence of the plasma proteome on complex diseases","volume":"52","author":"Zheng","year":"2020","journal-title":"Nat Genet"},{"key":"2025040212140435000_keae475-B6","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1038\/sj.bjp.0702689","article-title":"IL-12 as a therapeutic target for pharmacological modulation in immune-mediated and inflammatory diseases: regulation of T helper 1\/T helper 2 responses","volume":"127","author":"Hask\u00f3","year":"1999","journal-title":"Br J Pharmacol"},{"key":"2025040212140435000_keae475-B7","doi-asserted-by":"crossref","first-page":"6519","DOI":"10.1038\/s41467-022-34311-8","article-title":"Genome-wide association study identifies Sj\u00f6gren\u2019s risk loci with functional implications in immune and glandular cells","volume":"13","author":"Khatri","year":"2022","journal-title":"Nat Commun"},{"key":"2025040212140435000_keae475-B8","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41586-018-0175-2","article-title":"Genomic atlas of the human plasma proteome","volume":"558","author":"Sun","year":"2018","journal-title":"Nature"},{"key":"2025040212140435000_keae475-B9","first-page":"329","article-title":"Plasma proteomic associations with genetics and health in the UK Biobank","volume-title":"Nature","year":"2023"},{"key":"2025040212140435000_keae475-B10","article-title":"Integrative proteomic analyses across common cardiac diseases yield new mechanistic insights and enhanced prediction [Internet]","author":"Schuermans","year":"2023","journal-title":"medRxiv"},{"key":"2025040212140435000_keae475-B11","doi-asserted-by":"crossref","first-page":"k601","DOI":"10.1136\/bmj.k601","article-title":"Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians","volume":"362","author":"Davies","year":"2018","journal-title":"BMJ"},{"key":"2025040212140435000_keae475-B12","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/j.ajhg.2022.04.001","article-title":"Combining evidence from Mendelian randomization and colocalization: review and comparison of approaches","volume":"109","author":"Zuber","year":"2022","journal-title":"Am J Hum Genet"},{"key":"2025040212140435000_keae475-B13","doi-asserted-by":"crossref","first-page":"n2233","DOI":"10.1136\/bmj.n2233","article-title":"Strengthening the reporting of observational studies in epidemiology using Mendelian randomisation (STROBE-MR): explanation and elaboration","volume":"375","author":"Skrivankova","year":"2021","journal-title":"BMJ"},{"key":"2025040212140435000_keae475-B14","doi-asserted-by":"crossref","first-page":"3548","DOI":"10.3390\/ijms19113548","article-title":"Interferons and dry eye in Sj\u00f6gren\u2019s syndrome","volume":"19","author":"Ogawa","year":"2018","journal-title":"Int J Mol Sci"},{"key":"2025040212140435000_keae475-B15","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1111\/j.0300-9475.2004.01432.x","article-title":"Circulating cytokines in primary Sj\u00f6gren\u2019s syndrome determined by a multiplex cytokine array system","volume":"59","author":"Szodoray","year":"2004","journal-title":"Scand J Immunol"},{"key":"2025040212140435000_keae475-B16","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1038\/s41584-023-00991-9","article-title":"A leading role for interferon as a treatment target in Sj\u00f6gren syndrome","volume":"19","author":"Verstappen","year":"2023","journal-title":"Nat Rev Rheumatol"},{"key":"2025040212140435000_keae475-B17","doi-asserted-by":"crossref","first-page":"535","DOI":"10.4161\/mabs.3.6.17815","article-title":"Discovery and mechanism of ustekinumab","volume":"3","author":"Benson","year":"2011","journal-title":"mAbs"},{"key":"2025040212140435000_keae475-B18"},{"key":"2025040212140435000_keae475-B19","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.coi.2020.10.014","article-title":"Type I interferon in the pathogenesis of systemic lupus erythematosus","volume":"67","author":"Postal","year":"2020","journal-title":"Curr Opin Immunol"},{"key":"2025040212140435000_keae475-B20","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1136\/ard-2022-222839","article-title":"Clinical trials in systemic lupus erythematosus: the dilemma\u2014why have phase III trials failed to confirm the promising results of phase II trials?","volume":"82","author":"Lorenzo-Vizcaya","year":"2023","journal-title":"Ann Rheum Dis"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keae475\/59972621\/keae475.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/4\/2295\/59972621\/keae475.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/4\/2295\/59972621\/keae475.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T16:28:42Z","timestamp":1743611322000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/64\/4\/2295\/7747835"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,2]]},"references-count":20,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,9,2]]},"published-print":{"date-parts":[[2025,4,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keae475","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,4]]},"published":{"date-parts":[[2024,9,2]]}}}